Genmab A/S

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: DK0010272202
DKK
2,062.00
39 (1.93%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

94.08 k

Shareholding (Jun 2025)

FII

0.04%

Held by 5 FIIs

DII

99.96%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

DKK 130,596 Million ()

stock-summary
P/E

16.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.88

stock-summary
Return on Equity

27.45%

stock-summary
Price to Book

3.57

Revenue and Profits:
Net Sales:
6,085 Million
(Quarterly Results - Jun 2025)
Net Profit:
2,210 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
18.17%
0%
18.17%
6 Months
43.34%
0%
43.34%
1 Year
34.9%
0%
34.9%
2 Years
-6.1%
0%
-6.1%
3 Years
-37.08%
0%
-37.08%
4 Years
-16.08%
0%
-16.08%
5 Years
-11.99%
0%
-11.99%

Genmab A/S for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
16.94%
EBIT Growth (5y)
3.02%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.61
Sales to Capital Employed (avg)
0.46
Tax Ratio
13.91%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.04%
ROCE (avg)
125.56%
ROE (avg)
18.85%
Valuation key factors
Factor
Value
P/E Ratio
16
Industry P/E
Price to Book Value
4.19
EV to EBIT
15.35
EV to EBITDA
15.35
EV to Capital Employed
8.00
EV to Sales
5.31
PEG Ratio
0.29
Dividend Yield
NA
ROCE (Latest)
52.10%
ROE (Latest)
25.96%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 5 Foreign Institutions (0.04%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 12.64% vs 28.68% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 56.97% vs 3.76% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "6,084.60",
          "val2": "5,402.00",
          "chgp": "12.64%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "2,368.10",
          "val2": "1,816.00",
          "chgp": "30.40%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "59.20",
          "val2": "19.00",
          "chgp": "211.58%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-176.00",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "2,210.20",
          "val2": "1,408.00",
          "chgp": "56.97%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "389.20%",
          "val2": "336.20%",
          "chgp": "5.30%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 30.67% vs 13.57% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 80.24% vs -20.18% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "21,526.00",
          "val2": "16,474.00",
          "chgp": "30.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "7,416.00",
          "val2": "5,648.00",
          "chgp": "31.30%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "120.00",
          "val2": "27.00",
          "chgp": "344.44%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-300.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "7,844.00",
          "val2": "4,352.00",
          "chgp": "80.24%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "325.30%",
          "val2": "323.00%",
          "chgp": "0.23%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
6,084.60
5,402.00
12.64%
Operating Profit (PBDIT) excl Other Income
2,368.10
1,816.00
30.40%
Interest
59.20
19.00
211.58%
Exceptional Items
0.00
-176.00
100.00%
Consolidate Net Profit
2,210.20
1,408.00
56.97%
Operating Profit Margin (Excl OI)
389.20%
336.20%
5.30%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is 12.64% vs 28.68% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 56.97% vs 3.76% in Jun 2024

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
21,526.00
16,474.00
30.67%
Operating Profit (PBDIT) excl Other Income
7,416.00
5,648.00
31.30%
Interest
120.00
27.00
344.44%
Exceptional Items
-300.00
0.00
Consolidate Net Profit
7,844.00
4,352.00
80.24%
Operating Profit Margin (Excl OI)
325.30%
323.00%
0.23%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 30.67% vs 13.57% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 80.24% vs -20.18% in Dec 2023

stock-summaryCompany CV
About Genmab A/S stock-summary
stock-summary
Genmab A/S
Pharmaceuticals & Biotechnology
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer, with a focus on solid tumors and hematological cancer. The Company has two approved antibodies: DARZALEX (daratumumab) and Arzerra (ofatumumab). DARZALEX is approved in combination with other standard therapies in frontline multiple myeloma, relapsed/refractory multiple myeloma and as a monotherapy for heavily pretreated or double-refractory multiple myeloma. It is marketed in the United States (U.S.), Europe and Japan. Arzerra is approved in certain territories for various chronic lymphocytic leukemia (CLL) indications and is marketed in the U.S. and Japan. The Company also develops a broad clinical and pre-clinical product pipeline, both own and partnered, and owns four proprietary antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
Company Coordinates stock-summary
Company Details
Kalvebod Brygge 43 , KOEBENHAVN V None : 1560
stock-summary
Tel: 45 7020272845 3 3779558
stock-summary
Registrar Details